Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
Makaleler > Tam Makale · 2016
Yazarlar: Maurice Perol, Tudor-Eliade Ciuleanu, Oscar ARRİETA, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay GÖKSEL, Keunchil Park, Ruben Dario KOWALYSZYN, Joanna PİKİEL, Conrad R. Lewanski, Michael Thomas, Shaker Dakhil, Joo-Hang Kim, Nina Karaseva, Sergey Yurasov, Annamaria Zimmermann, Pablo LEE, Gebra Cuyun Carter, Martin Reck, Federico CAPPUZZO, Edward B. Garon
Lung Cancer, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2016, cilt 93, ss 95-103
DOI: 10.1016/j.lungcan.2016.01.007
Özet
Objectives: REVEL demonstrated that ramucirumab + docetaxel (RAM + DTX) improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic non-small cell lung cancer with progression after platinum-based chemotherapy. This analysis examined quality of life (QoL) as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.